Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?

Robert Dziura; Paweł Macek; Jolanta Smok-Kalwat; Stanisław Góźdź

doi:10.5114/ms.2020.96795

eISSN: 2300-6722
ISSN: 1899-1874

Medical Studies/Studia Medyczne

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2020
vol. 36

Send email

Copy url:

abstract:

Review paper

Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?

Robert Dziura

¹

,

Paweł Macek

^{2, 3}

,

Jolanta Smok-Kalwat

¹

,

Stanisław Góźdź

^{1, 2}

Department of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland

Collegium Medicum, Jan Kochanowski University, Kielce, Poland

Department of Epidemiology and Cancer Control, Holy Cross Cancer Centre, Kielce, Poland

Medical Studies/Studia Medyczne 2020; 36 (2): 142–147

DOI: https://doi.org/10.5114/ms.2020.96795

Online publish date: 2020/06/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Dziura R, Macek P, Smok-Kalwat J, Góźdź S. Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?. Medical Studies/Studia Medyczne. 2020;36(2):142-147. doi:10.5114/ms.2020.96795.

APA

Dziura, R., Macek, P., Smok-Kalwat, J.,  & Góźdź, S. (2020). Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?. Medical Studies/Studia Medyczne, 36(2), 142-147. https://doi.org/10.5114/ms.2020.96795

Chicago

Dziura, Robert, Paweł Macek, Jolanta Smok-Kalwat,  and Stanisław Góźdź. 2020. "Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?". Medical Studies/Studia Medyczne 36 (2): 142-147. doi:10.5114/ms.2020.96795.

Harvard

Dziura, R., Macek, P., Smok-Kalwat, J.,  and Góźdź, S. (2020). Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?. Medical Studies/Studia Medyczne, 36(2), pp.142-147. https://doi.org/10.5114/ms.2020.96795

MLA

Dziura, Robert et al. "Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?." Medical Studies/Studia Medyczne, vol. 36, no. 2, 2020, pp. 142-147. doi:10.5114/ms.2020.96795.

Vancouver

Dziura R, Macek P, Smok-Kalwat J, Góźdź S. Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?. Medical Studies/Studia Medyczne. 2020;36(2):142-147. doi:10.5114/ms.2020.96795.

PlumX metrics:

The incidence of pancreatic cancer has been increasing in recent years. It is expected to be the second or the third leading cause of cancer deaths in high-income countries in the next decade. Standard therapeutic management for patients with resectable pancreatic cancer is surgical resection followed by adjuvant chemotherapy. The main reason for neoadjuvant therapy is that the prognosis with current strategies is unsatisfactory, and we need new treatments to improve overall survival as well as the quality of life of the patients suffering from pancreatic cancer. The aim of this paper is to provide an overview of the recent data on the subject of neoadjuvant treatment concerning resectable and borderline resectable group of patients.

keywords:

Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?

Robert Dziura 1 , Paweł Macek 2, 3 , Jolanta Smok-Kalwat 1 , Stanisław Góźdź 1, 2

pancreatic cancer, neoadjuvant treatment, chemotherapy

Robert Dziura

¹

,

Paweł Macek

^{2, 3}

,

Jolanta Smok-Kalwat

¹

,

Stanisław Góźdź

^{1, 2}